Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod and Danazol in Steroid-resistant/Relapse ITP
NCT05281068Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iguratimod in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
iguratimod
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05281068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281068.